Local injection of lentivirus-delivered livinshrna suppresses lung adenocarcinoma growth by inducing a G0/G1 phase cell cycle arrest

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 8, 2012, Pages 796-805

  Chen, Yu Sheng ^a   Li, Hong Ru ^a   Miao, Yan ^a   Chen, Wen Ying ^a   Li, You Tang ^a   Wang, Gui Qing ^a   Wu, Zheng Cai ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Livin gene; Lung adenocarcinoma; RNA interference; Xenograft tumor model

Indexed keywords

ADAPTOR PROTEIN; BIRC7 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; TUMOR PROTEIN;

ADENOCARCINOMA; ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL CYCLE G0 PHASE; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE SILENCING; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; LENTIVIRINAE; LUNG TUMOR; MALE; METHODOLOGY; MOUSE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; G0 PHASE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LENTIVIRUS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870463195     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Dean EJ, Ranson M, Blackhall F, Holt SV, Dive C. Novel therapeutic targets in lung cancer: inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat Rev 2007; 33: 203-12.
2. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543-68.
3. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006; 3: 179-88.
4. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008; 12: 463-76.
5. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 2001; 495: 56-60.
6. Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH, Jung HL, Koo HH, Kim HJ, Kang HJ, Shin HY, Ahn HS. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 2007; 109: 471-7.
7. Hariu H, Hirohashi Y, Torigoe T, Asanuma H, Hariu M, Tamura Y, Aketa K, Nabeta C, Nakanishi K, Kamiguchi K, Mano Y, Kitamura H, Kobayashi J, Tsukahara T, Shijubo N, Sato N. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res 2005; 11: 1000-09.
8. Nedelcu T, Kubista B, Koller A, Sulzbacher I, Mosberger I, Arrich F, Trieb K, Kotz R, Toma CD. Livin and Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin Oncol 2008; 134: 237-44.
9. Kempkensteffen C, Hinz S, Krause H, Jager T, Köllermann J, Weikert S, Christoph F, Schostak M, Miller K, Schrader M. Expression of splicing variants of the inhibitor of apoptosis Livin in testicular germ cell tumors. Tumour Biol 2008; 29: 76-82.
10. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276: 3238-46.
11. Yang YL, Lin SR, Chen JS, Lin SW, Yu SL, Chen HY, Yen CT, Lin CY, Lin JF, Lin KH, Jou ST, Hu CY, Chang SK, Lu MY, Chang HH, Chang WH, Lin KS, Lin DT. Expression and prognostic significance of the apoptotic genes BCL2L13, Livin, and CASP8AP2 in childhood acute lymphoblastic leukemia. Leuk Res 2010; 34: 18-23.
12. Liu HB, Kong CZ, Zeng Y, Liu XK, Bi JB, Jiang YJ, Han S. Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment. Urol Oncol 2009; 27: 277-83.
13. Wang X, Xu J, Ju S, Ni H, Zhu J, Wang H. Livin gene plays a role in drug resistance of colon cancer cells. Clin Biochem 2010; 43: 655-60.
14. Sun JG, Liao RX, Zhang SX, Duan YZ, Zhuo WL, Wang XX, Wang ZX, Li DZ, Chen ZT. Role of Inhibitor of Apoptosis Protein Livin in Radiation Resistance in Nonsmall Cell Lung Cancer. Cancer Biother Radiopharm 2011; 26: 585-92.
15. Crnković-Mertens I, Muley T, Meister M, Hartenstein B, Semzow J, Butz K, Hoppe-Seyler F. The anti-apoptotic livin gene is an important determinant for the apoptotic resistance of non-small cell lung cancer cells. Lung Cancer 2006; 54: 135-42.
16. Chang H, Schimmer AD. Schimmer Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther 2007; 6: 24-30.
17. Crnković-Mertens I, Wagener N, Semzow J, Gröne EF, Haferkamp A, Hohenfellner M, Butz K, Hoppe-Seyler F. Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci 2007; 64: 1137-44.
18. Liu B, Han M, Wen JK, Wang L. Livin/ML-IAP as a new target for cancer treatment. Cancer Lett 2007; 250: 168-76.
19. Sumimoto H, Kawakami Y. The RNA silencing technology applied by lentiviral vectors in oncology. Methods Mol Biol 2010; 614: 187-99.
20. Chen YS, Li HR, Lin M, Chen G, Xie BS, Xu NL, Lin LF. Livin abrogates apoptosis of SPC-A1 cell by regulating JNKI signaling pathway. Mol Biol Rep 2010; 37: 2241-47.
21. Antonaci A, Consorti F, Mardente S, Natalizi S, Giovannone G, Della Rocca C. Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma. Oncol Rep 2008; 20: 63-7.
22. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by surviving. Nature 1998; 396: 580-4.
23. Connell CM, Wheatley SP, McNeish IA. Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Res 2008; 68: 7923-31.
24. Golias CH, Charalabopoulos A, Charalabopoulos K. Cell proliferation and cell cycle control: a mini review. Int J Clin Pract 2004; 58: 1134-41.
25. Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C, Roncalli M, Coggi G, Bosari S. Inhibitors of apoptosis proteins (IAPs)expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 2009; 9: 125.
26. Wang L, Zhang Q, Liu B, Han M, Shan B. Challenge and promise: roles for Livin in progression and therapy of cancer. Mol Cancer Ther 2008; 7: 3661-69.
27. Li H, Chen Y, Chen G, Xie B, Lin L. Expression of livin protein in lung cancer and its relation with the expression of pro-caspase3 protein. Zhongguo Fei Ai Za Zhi 2008; 11: 729-33.
28. Oh BY, Lee RA, Kim KH. siRNA targeting Livin decreases tumor in a xenograft model for colon cancer. World J Gastroenterol 2011; 17: 2563-71.
29. Wang H, Tan SS, Wang XY, Liu DH, Yu CS, Bai ZL, He DL, Zhao J. Silencing Livin gene by siRNA leads to apoptosis induction, cell cycle arrest, and proliferation inhibition in malignant melanoma LiBr cells. Acta Pharmacol Sin 2007; 28: 1968-74.
30. Eymin B, and Gazzeri S. Role of cell cycle regulators in lung carcinogenesis. Cell Adh Migr 2010; 4: 114-23.
31. Wang L, Lu A, Liu X, Sang M, Shan B, Meng F, Cao Q, Ji X. The flavonoid Baohuoside-I inhibits cell growth and downregulates survivin and cyclin D1 expression in esophageal carcinoma via β-catenin-dependent signaling. Oncol Rep 2011; 26: 1149-56.
32. Ye L, Song X, Li S, Yang D, Zhang J, Che X, Chen X, Wang J, Zhang Z. Livin-alpha promotes cell proliferation by regulating G1-S cell cycle transition in prostate cancer. Prostate 2011; 71: 42-51.
33. Chu J, Wu S, Xing D. Survivin mediates selfprotection through ROS/cdc25c/CDK1 signaling pathway during tumor cell apoptosis induced by high fluence low-power laser irradiation. Cancer Lett 2010; 297: 207-19.
34. Samuel T, Okada K, Hyer M, Welsh K, Zapata JM, Reed JC. cIAP1Localizes to the nuclear compartment and modulates the cell cycle. Cancer Res 2005; 65: 210-8.